Maegim한국어

중앙백신

072020KOSDAQSector: Pharma & Biotech
₩9,380▲ 2.74%Market cap ₩88.7BAs of Jul 21, 2026 close · updated once daily
A
Grade A70.7 ptsTop 10% of 2,523 stocks
Financial strength
78.4
Growth momentum
55.3
Price attractiveness
72.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

78.4
How much debt does it carry relative to equity?
Debt-to-equity ratio
16.6%
✓ Above median · Top 18.1% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
426.8%
✓ Above median · Top 29.1% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
13.2%
✓ Above median · Top 13.8% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
5.8%
✓ Above median · Top 25.4% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

55.3
How much did revenue grow in a year?
Revenue growth (YoY)
7.6%
✓ Above median · Top 46.3% in sector
Sector median 6.4%
Did core profits grow in a year?
Operating income change (YoY)
12.5%
✓ Above median · Top 43.1% in sector
Sector median 3.6%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

72.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
14.4x
✓ Above median · Top 21.3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.84x
✓ Above median · Top 33.1% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15